News Hub | News Direct

Technology

Artificial Intelligence Big Data Cloud Computing Cyber Security Data Management Electronics Enterprise & Network Technology Financial Technology Hardware Mobile & Wireless Nanotechnology Semiconductor Software Telecommunications
Article thumbnail News Release

Former Analyst at Ark Invest Bullish on Solana - Where Next For Dogecoin and Everlodge?

Total Media

Chris Burniske, a former analyst at Ark Invest, is bullish on the future of Solana (SOL), and investors are diversifying with the cryptocurrency. In addition, Dogecoin (DOGE) and Everlodge (ELDG) are also getting significant attention following their recent price movements. Today, we will jump into the price performance for each crypto to see how far they can spike. Summary Solana is projected to climb in value to $29.22 by the end of 2023 Dogecoin can climb as high as $0.098 by the end of Q4 Everlodge to rise in value by 2,500% at launch Chris Burniske Is Bullish on the Future of Solana (SOL) Solana (SOL) has recently been in the spotlight as it achieved a significant price upswing. With its recent milestone in mind, analysts are bullish on its future. Chris Burniske, a former analyst at Ark Invest, for example, observed how there are several factors that indicate a bullish performance for Solana. The coin's recent price against Ethereum is the foremost indicator. It achieved the 0.02 mark against ETH, which indicates a strong market acceptance and confidence in its future. This breakthrough suggests a potential trajectory towards its next threshold. The Solana trading volume jumped 28% during the past 24 hours. In addition, its value increased from $30.13 to $36.78. In the past two weeks, Solana is up 51.5%. According to the Solana price prediction, it will experience a price upswing to $29.22 by the end of 2023. Dogecoin (DOGE) to See a Rapid Upswing Dogecoin (DOGE) recently saw a price upswing, and analysts are bullish on its future. During the previous week, the price of the Dogecoin crypto moved from $0.065 to $0.074, making $0.080 its next major resistance point. However, the Dogecoin market cap is at $9,799,553,676, and it has remained the 10th largest crypto on the market. According to the current Dogecoin price prediction, it can reach as high as $0.098 by the end of 2023. While this is a bullish outlook, Dogecoin was not the only altcoin to grab attention. Everlodge (ELDG) Can Rise in Value by 2,500% at Launch Everlodge (ELDG) is an upcoming marketplace that will enable anyone to access luxurious properties at a fraction of the cost. In addition, it will eliminate key issues that are plaguing the market. These include high costs of entry, lack of accessibility, and lack of transparency. The properties will get minted as NFTs and, as a result, will enable anyone the opportunity to jump into making investments through the usage of blockchain technology. These NFTs will get split into numerous smaller parts, where investors can begin buying a fraction starting at $100. This means that without needing a lot of upfront capital, anyone can build a diversified portfolio through which they can get passive income, assuming they are rental properties. ELDG can also be staked for passive income, and it is also used for governance. This native token is now at Stage 6 of the presale offered at $0.023. At launch, the crypto can surge as high as 2,500%. For more information about the Everlodge (ELDG) Presale you can visit their website or join their community here. Contact Details Media Team media@everlodge.io

November 03, 2023 11:00 AM Eastern Daylight Time

Article thumbnail News Release

The AI Image Generator Taking User Creativity to New Frontiers

Hotimage.AI

Artificial intelligence has amazed many with its applications in AI chat, such as ChatGPT. However, AI has also revolutionized the field of image generation. Gone are the days when users needed to spend hours on Photoshop to design a new photo. Now, they can rely on platforms that swiftly bring their ideas to life and transform them into images with the help of an AI image generator. One of the newest AI image generator platforms is hotimage.ai, this site aims to empower users to explore their creativity. It is an easy-to-use and free website where users can delve into their artistic style across various categories, including support for NSFW AI generated images. "The platform's concept is to provide users with a safe environment for crafting images from scratch, without requiring technical expertise, while ensuring that their ideas and fantasies are brought to life with the utmost realism," said Elizabeth Carter, the CEO of hotimage.ai. Key highlights of hotimage.ai include: Realistic Images: The platform creates images that appear real and precise within seconds. Hotimage.ai generates high-quality visual content, suitable for various fields like advertising, entertainment, and product design. Copyright-Free Images: Users can download and utilize images created by the platform without the need for real subjects or models. Speed and Security: The platform can generate lifelike images within seconds while ensuring complete anonymity and security. Versatility: Offering a wide range of options for image generation, hotimage.ai allows users to craft their photos and explore different styles, including animation, artistic renditions, portraits, and AI NSFW content. Using hotimage.ai is simple, just visit the website, choose the desired image category, and begin selecting from the available options. For instance, if you're creating an image featuring a model, you can select various options such as hairstyle, hair color, facial expressions, and background settings. After making your selections, click on "generate," and the platform will swiftly create the desired picture within seconds. Utilizing Artificial Intelligence, AI image generator sites offer a myriad of possibilities in various artistic styles. Users simply provide the details or a general idea, including their "must-haves," and the AI image generator will transform these instructions into a picture within seconds. Contact Details Hotimage.AI support@hotimage.ai Official Website https://hotimage.ai/ Contact Details Adam Scott +1 346-428-8364 support@hotimage.ai

November 03, 2023 10:33 AM Eastern Daylight Time

Image
Article thumbnail News Release

Tron Continues Its Uptrend, Bitcoin Cash Is Stagnant, BorroeFinance Investors Are Bullish

Blockchain Digest

Per recent market data, Tron (TRX) is in a sustained rally alongside its Total Value Locked (TVL), which has just obtained a record high. On the flip side, Bitcoin Cash (BCH) continues its protracted passiveness as the bulls struggle to overhaul the bears. Meanwhile, investors remain bullish on the new DeFi project BorroeFinance ($ROE) as it gears up for a parabolic surge. Let’s find out which of these top crypto coins investors may likely delve into. >>BUY $ROE TOKENS NOW<< Tron Surges 9% As TVL Hits All-time High On October 28, market data revealed an impressive development within the Tron (TRX) chain. Accordingly, Tron (TRX) has managed to perform excellently in recent times, setting new records. In particular, the blockchain authorized 6.5 billion transactions, indicating the efficacy and robustness of the Tron (TRX) network. At the same time, Tron’s Total Value Locked (TVL) hit a new milestone of $6.75 billion, accompanied by a 2.23% increase. These impressive demonstrations significantly affected Tron’s native token, TRX. Notably, TRX registered a 9.27% increase between October 16 and October 29. During this period, Tron (TRX) rose from $0.0866 to $0.0948. Due to Tron’s current trajectory, analysts posit that TRX is bound to climb to higher levels. More precisely, they expect to see TRX gain 4.3% to $0.1 in the coming term. Miners Are Dilemmatic Over Bitcoin Cash On-chain activities data showed that Bitcoin Cash (BCH) miners have been on a selling spree over the past month. This selloff resulted in a massive drop in the price of Bitcoin Cash (BCH). On October 24, BCH withdrew from the $265 price range following a period of sharp correction. This pullback represented a 3.85% drop in the price of Bitcoin Cash (BCH). However, as the selloff slowed down, Bitcoin Cash (BCH) witnessed an impulsive bounce. On the weekly timeframe, BCH gained 13.16% on its market value between October 16 and October 22. However, the selling pressure eventually weighed heavily on Bitcoin Cash as BCH only rose 1.11% between October 23 and October 29. This slowdown in activity led experts to assert that Bitcoin Cash (BCH) might maintain this pace in the forthcoming sessions. As a result, they predict that BCH may linger around $242, a 0.1% increase from the current price until significant news or development touching Bitcoin Cash surfaces. BorroeFinance Investors Are Bullish On $ROE BorroeFinance ($ROE) is regarded as one of the best cryptocurrency investment options for both savvy and novice investors. This sentiment is predicated on the capabilities of the platform and the growth map of $ROE. BorroeFinance caters to the needs of buyers and sellers in the Web3 space, making it a pivotal project for people involved in Web3. >>BUY $ROE TOKENS NOW<< BorroeFinance is a marketplace that uses artificial intelligence tools to carry out its services to users. It offers content creators within the Web3 world a platform to trade their future earnings for instant greenbacks. The platform connects buyers and sellers while ensuring that the needs of both parties are duly served. The reason BorroeFinance is considered one of the top DeFi projects in existence is because of its impact on the finance world. BorroeFinance ($ROE) helps businesses and individuals raise funds through an easy and less hectic procedure. The platform is targeted to launch on the Polygon blockchain alongside its native token, $ROE. BorroeFinance is currently in Stage 2 of its public presale, with $ROE trading at $0.015. Investors have the opportunity to benefit from a 167% surge when $ROE hits $0.040 at the end of the presale. Not only that, the token’s value is bound to increase after its official launch on exchanges, creating borderless avenues for investors to earn. Learn more about BorroeFinance ($ROE) here: Visit BorroeFinance Presale | Join The Telegram Group | Follow BorroeFinance on Twitter Contact Details Borroe Finance media@borroefinance.ai

November 03, 2023 10:07 AM Eastern Daylight Time

Article thumbnail News Release

Arbitrum Dominates Layer 2 Protocols, BorroeFinance Empowers Web3 Growth Using AI

Blockchain Digest

Arbitrum (ARB) recently recorded another ecosystem win that further cemented its top position among L2 blockchains. While Arbitrum (ARB) built a program that will help developers build better Dapps, BorroeFinance ($ROE) is promoting web3 growth by bridging short-term liquidity gaps in the industry. Let’s see what experts are saying about these two tokens and their predictions for the future. >>BUY $ROE TOKENS NOW<< ARB Surges Amid Positive Ecosystem Development On October 26, Arbitrum (ARB) announced that its long-anticipated Arbitrum Orbit is ‘mainnet-ready.’ The Arbitrum Orbit project will allow blockchain developers to build decentralized apps and new DeFi projects with cutting-edge technology. In addition, developers can create their customized L3 blockchain on any Arbitrum L2 blockchain. The Arbitrum Orbit project has put Arbitrum (ARB) ahead of other L2 blockchains like Optimism and Polygon. Steven Goldfeder, CEO of Offchain Labs, also shared his opinions on the functionalities of Arbitrum Orbit. The CEO said this level of customization and flexibility is a game changer. Arbitrum Orbit will open doors to a new sub-group of L3 blockchain engineers, resulting in an ecosystem expansion. As a result of this positive ecosystem development, ARB gained 9.51% in the last week of October. On October 23, ARB traded at $0.8732. A week later, ARB surged and traded at $0.9591. According to analysts, ARB is at the beginning of its bull rally, and the token could hit $1.5500 in Q1 2024. BorroeFinance: AI Meets Blockchain in New Decentralized Fundraising Platform BorroeFinance ($ROE) is the world’s first web3 blockchain invoice discounting NFT marketplace. This AI-powered fundraising platform allows web3 businesses to generate instant cash by selling future digital earnings. Web3 participants on BorroeFinance ($ROE) can mint their future subscriptions, invoices, and royalties into popular NFTs and sell them to supportive communities at discounted prices. >>BUY $ROE TOKENS NOW<< Supportive communities are active followers on your web3 brand willing to support your business by providing loans to meet immediate short-term liquidity needs. BorroeFinance protects buyer investments by incorporating AI risk assessment, efficient payment solutions, and blockchain technology into its protocol. According to experts, this loan request protocol will guarantee a safe, secure, and straightforward fundraising process. Thankfully, this high-utility project is still in its early stages, and savvy investors are buying the $ROE for $0.015. When $ROE finally hits the mainstream market, the token will surge 167% and trade for $0.040 on major crypto exchanges. If expert predictions play out, $ROE will record fast market adoption and may trade for $0.100 by June 2024. Learn more about BorroeFinance ($ROE) here: Visit BorroeFinance Presale | Join The Telegram Group | Follow BorroeFinance on Twitter Contact Details Borroe Finance media@borroefinance.ai

November 03, 2023 10:05 AM Eastern Daylight Time

Article thumbnail News Release

Elicio Therapeutics (NASDAQ: ELTX) Reports Promising Progress In Cancer Vaccine Clinical Trials, Placing An Emphasis On The Lymphatic System

Benzinga

By Jeremy Golden, Benzinga An estimated 609,820 people will die of cancer in the United States this year, according to the National Cancer Institute. Promising results from a 12-year-old clinical-stage biotechnology company have experts optimistic about the future of treating this deadly disease. With its proprietary Amphiphile or “AMP” platform, Elicio Therapeutics Inc. (NASDAQ: ELTX) has developed multiple cancer vaccine candidates that concentrate an array of different immunogens in the lymph nodes. ELI-002 is Elicio’s lead clinical program for Kirsten rat sarcoma (KRAS) driven cancers caused by a mutation of the KRAS gene. An “off the shelf” approach designed to stimulate an immune response against the seven KRAS mutations driving 25% of solid tumors, ELI-002 is currently being studied in AMPLIFY-201 – a phase 1 dose escalation study – and AMPLIFY-7P, a phase 1/2 study. In September, Elicio released new information about the vaccine candidates in its pipeline at the ninth AACR Special Conference on Pancreatic Cancer in Boston. The positive preliminary relapse-free survival (RFS) data from the ongoing AMPLIFY-201 study demonstrated an 86% reduction in risk of progression or death in patients with large T-cell responses induced by ELI-002 2P, a 2-peptide formulation designed to treat cancers driven by G12D and G12R mutations in KRAS. Despite the AMPLIYF-201 study not including a control arm, the median RFS of over 16 months is significantly longer than what has been seen in other studies of similar patient groups. “Patients with mutant KRAS cancers, particularly pancreatic and colorectal cancers, have a poor prognosis with limited treatment options when tumor DNA or protein biomarkers are detected after standard surgery and chemotherapy,” said Eileen M. O’Reilly, M.D., Winthrop Rockefeller Endowed Chair of Medical Oncology and Co-Director of Medical Initiatives at David M. Rubenstein Center for Pancreatic Cancer Research. “We are encouraged by the early data showing ELI-002 induced T cells can positively impact clinical endpoints including the risk of relapse and death in this study.” Targeting Immunogens To Lymph Nodes Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunogens in the lymph nodes, which are located throughout the body on the lymphatic vessels at various intervals along the lymphatic routes. During the process of circulating throughout the lymphatic system, lymph fluid accumulates antigens and other biomolecules captured from the tissues. This fluid then drains into the lymph nodes, where it encounters T cells and B cells congregating together with antigen-presenting cells (APCs). Targeting the immunogens in the lymph nodes has been proven to result in tumor or pathogen-targeted immunity, including potent T cell and humoral responses, in preclinical trials. Alongside AMPLIFY-201, ELI-002 7P is currently being studied in AMPLIFY-7P, a phase 1/2 trial in patients with high relapse risk mKRAS-driven solid tumors. Designed to provide immune response coverage against seven of the most common KRAS mutations, the ELI-002 7P formulation increases the potential patient population for ELI-002 while possibly reducing the chance of bypassing resistance mechanisms. Moving forward in early 2024, Elicio Therapeutics plans to initiate a randomized phase 2 trial studying ELI-002 7P as a monotherapy in adjuvant PDAC patients. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 03, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Preparing for Mexico’s TIIE Transition: Lessons from LIBOR

Tradeweb

The clock is ticking louder on the transition to a new overnight funding rate benchmark for Mexico’s $4.9 trillion swaps market. As we shared in our recent post, Mexico’s TIIE-28 Benchmark is About to Go the Way of LIBOR; Are You Ready?, the Tasa de Interés Interbancaria de Equilibrio, or Interbank Equilibrium Interest Rate (TIIE) will gradually move to a new standard, the TIIE de Fondeo (F-TIIE), starting on January 1, 2024. While many market participants have already begun making the transition and others are busy hammering out their plans, there is still no discernable liquidity benchmarked to the new standard and many questions remain about how, exactly, the marketplace will respond when the switch is flipped next year. Fortunately, we’ve been through this before, and many of the lessons learned over the course of the recent LIBOR migration are also applicable to F-TIIE. Best Practices for a Smooth Transition As a hub of swaps trading activity, Tradeweb played a central role in the transition from LIBOR to the Secured Overnight Financing Rate (SOFR). Now we are working with our clients and Banco de México to share insights and advice on how to navigate the challenges that will inevitably accompany the TIIE transition. We’ve identified several best practices for market participants to prepare for the fast-approaching deadlines, which are January 2024 and January 2025. Collaboration is Key: LIBOR earned its reputation as “the world’s most important number” over the course of a 30-year run, during which it became the interest rate benchmark for hundreds of trillions of dollars of financial instruments globally. Transitioning away from that standard created countless valuation, trade processing and settlement details that needed to be sorted. But it’s important to note that the transition was made possible through close collaboration, including between market participants and regulators who coordinated efforts ahead of target deadlines and communicated frequently. That same spirit of collaboration is already present in the F-TIIE transition, as various stakeholders have been working together to drive a successful outcome. Expect Bumps in the Road: Tradeweb conducted several analyses tracking liquidity in the swaps market throughout the LIBOR transition, monitoring trades benchmarked to LIBOR and those benchmarked to the new SOFR standard over several different time periods. One of our most interesting observations surrounded the July 26, 2021 “SOFR First” phased initiative, where we saw the implied cost of liquidity—as measured by bid-offer spreads—gradually tighten in the weeks and months leading up to the July 26 announcement, then subsequently tighten further. The lesson learned here was that while there was a premium on liquidity using the new benchmark for a short time, but that premium soon faded once the marketplace migrated to the new standard. Benchmark Transitions Happen Gradually, Then All at Once: Another lesson learned in the LIBOR transition was that, although many firms had already done the heavy lifting on preparing themselves to use the new benchmark, the actual adoption was gradual. In fact, the percentage of new U.S. dollar swaps trades benchmarked to SOFR and executed on the Tradeweb platform did not start to trend upward until August of 2021. From there, SOFR adoption grew slowly but steadily until it surged in January 2022 aligned with the regulatory deadline for no new LIBOR origination. The key takeaway here is that even though it may look like many firms have not yet made the conversion, most are in the process of getting ready and will be able to do so when the deadline hits. Electronification Helps: As was the case with LIBOR, the TIIE transition can be made easier for those trading electronically. Obvious benefits like direct integration with order management systems and built-in audit trail for clearing and settlement help to streamline the process. In addition, more advanced capabilities that are only available on electronic markets, such as trade compression tools -- which allow market participants to easily collapse old positions and roll them into a new index in a single transaction -- can ease the process of getting old positions onto the new benchmark. How We’re Helping Fortunately there are plenty of resources and opportunities available to market participants right now to prepare for the transition. One example is Tradeweb’s collaboration with the Banco de México who together in mid-November will convene stakeholders, including clearinghouses, dealers and the investor community to discuss key deadlines, transition strategies and navigating challenges. As we continue to observe and learn best practices from these market participants, we will continue to provide updates here to share what we’ve learned. About Tradeweb Markets Tradeweb Markets Inc. (Nasdaq: TW) is a leading, global operator of electronic marketplaces for rates, credit, equities and money markets. Founded in 1996, Tradeweb provides access to markets, data and analytics, electronic trading, straight-through-processing and reporting for more than 40 products to clients in the institutional, wholesale and retail markets. Advanced technologies developed by Tradeweb enhance price discovery, order execution and trade workflows while allowing for greater scale and helping to reduce risks in client trading operations. Tradeweb serves more than 2,500 clients in more than 65 countries. On average, Tradeweb facilitated more than $1.2 trillion in notional value traded per day over the past four quarters. For more information, please go to www.tradeweb.com. Forward-Looking Statements This release contains forward-looking statements within the meaning of the federal securities laws. Statements related to, among other things, our outlook and future performance, the industry and markets in which we operate, our expectations, beliefs, plans, strategies, objectives, prospects and assumptions and future events are forward-looking statements. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed under the heading “Risk Factors” in documents of Tradeweb Markets Inc. on file with or furnished to the SEC, may cause our actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements contained in this release are not guarantees of future performance and our actual results of operations, financial condition or liquidity, and the development of the industry and markets in which we operate, may differ materially from the forward-looking statements contained in this release. In addition, even if our results of operations, financial condition or liquidity, and events in the industry and markets in which we operate, are consistent with the forward-looking statements contained in this release, they may not be predictive of results or developments in future periods. Any forward-looking statement that we make in this release speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this release. Contact Details Daniel Noonan +1 646-767-4677 Daniel.Noonan@Tradeweb.com Company Website http://www.tradeweb.com

November 02, 2023 05:08 PM Eastern Daylight Time

Article thumbnail News Release

RDARS CEO says innovative autonomous drone security system is likely to take flight in 2024

RDARS

RDARS Inc. president and CEO Charles Zwebner tells Proactive's Stephen Gunnion the company is preparing for a large scaling up of sales of its innovative autonomous drone security system in 2024 after the company commenced commercialization in June 2023. The CSE-listed company has already started selling the Drone Eagle Watch Platforms as it continues to advance the technology. Discussions are also underway with various large security companies for potential joint ventures. The system consists of a drone nest and the drone itself, designed for security and surveillance purposes. It is equipped to autonomously respond to security breaches on a property, flying predetermined missions or manual interventions, and transmitting live data to a command center. The company is targeting residential, commercial, industrial, and government clients seeking enhanced security and surveillance capabilities. After receiving its first 'Beyond Line of Site' waiver from the US Federal Aviation Administration (FAA), Zwebner said the company continues to engage with the FAA to obtain a criteria blanket waiver, expected in 2024, which will enable it to scale up sales. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 02, 2023 02:48 PM Eastern Daylight Time

Video
Article thumbnail News Release

QuickNode Releases The On-Chain Report Q3: Stablecoins Hit 400K Daily Active Addresses

QuickNode

QuickNode, an end-to-end development platform for Web3 innovation, has released The On-Chain Report to highlight the developments in the blockchain industry in the third quarter of 2023. Prepared with Artemis, an institutional data platform for digital assets, The On-Chain Report provides a comprehensive overview of blockchain usage and investments in Q3 by examining consumer trends, developer activity and the investment landscape. Among the key findings of The On-Chain Report is the significant increase in stablecoin activity across blockchain networks. Stablecoins have become the most popular category as measured by daily active addresses (DAA), ending Q3 with over 400,000 average DAA. Stablecoin has also become the only category examined by the report that has shown growth in Q3 2023, outperforming DeFi, Social, Gaming and NFT categories Key takeaways from QuickNode’s On-Chain Report include: Consumer activity was dominated by financial activity, with stablecoin activity taking the crown from DeFi. Fueled primarily by the Friend.tech trend, DeSocial is starting to emerge with viral product launches. The potential for a Web2 scale social app will turn the current adoption levels on its head. Development activity remains strong only on Optimism’s OP Mainnet, suggesting that developers see EVM scaling solutions as a critical problem to solve in the near term. Future trends, as informed by investment data, suggest that gaming and AI offerings are where the blockchain ecosystem will see the greatest emergence in the coming years. Commenting on the report, QuickNode Co-founder and CEO, Dmitry Shklovsky said: “By centering the narrative around blockchain developers and end users, we gain valuable insights into the roadmap for building a sustainable and rapidly expanding Web3 ecosystem. These insights, combined with the context of product launches and investments, give us a comprehensive story of where we're heading.” Prepared by QuickNode and Artemis, The On-Chain Report draws an insightful picture of the blockchain industry by looking at today, medium term and long term. The report offers detailed stats and analyses categorized by Stablecoins, DeFi, NFT, Social dApps and EVM-scaling Solutions. To prepare the report, QuickNode has examined the average daily value on a weekly basis on Arbitrum One, Avalanche, Base, BNB Chain, Ethereum, OP Mainnet and Polygon PoS, using Artemis.xyz as the primary data source. The On-Chain Report is available here. About QuickNode Since its founding in 2017, QuickNode has emerged as the go-to solution for businesses and innovators requiring world-class blockchain development tools for speed, reliability, and security. Handling over eight billion blockchain requests daily, QuickNode boasts a 2.5X faster response time than competitors and 99.99% uptime across 24+ chains and 35+ networks. With a user-friendly interface and a robust multi-chain developer tool suite, QuickNode is an ideal choice for top Web3 businesses and global brands. About Artemis Since launching in 2022, Artemis has emerged as a premier institutional data platform for digital assets. Delivering insights across 25+ blockchains, Artemis stands out as the definitive data science layer for crypto fundamental information. From sector-specific metrics to real-time developer engagement insights, Artemis ensures that users are equipped with the most comprehensive and customizable digital asset data available. With its wide availability of data ingestion choices, from Excel integrations to Snowflake Data Shares, Artemis is the data platform of choice for global financial institutions and investors. Contact Details MarketAcross PR Kim Bazak Kim@marketacross.com Company Website https://www.quicknode.com/

November 02, 2023 02:00 PM Eastern Daylight Time

Image
Article thumbnail News Release

PathAI Announces New NASH/MASH Advisory Network to Guide Evidence Generation and Regulatory Strategy for AI-Powered Digital Pathology Product Development

PathAI

PathAI, a leading provider of precision pathology solutions, today announced the formation of a new advisory network to inform the company’s vision to leverage AI-powered digital pathology to improve outcomes for individuals with non-alcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis (NASH/MASH). According to the American Liver Foundation, approximately 2-5% of adults in the U.S. have NASH/MASH, a disease with no FDA-approved treatments currently available. Disease incidence has risen from 1.51% in 2010 to 2.79% in 2020. The American Liver Foundation predicts that by 2030, NASH/MASH will be the most frequent reason for liver transplants in the U.S., underscoring the severe impact of this disease. Given the burden of NASH/MASH and lack of available treatment options for patients, attention from industry and academia alike is increasing, with numerous clinical trials in progress to develop novel, efficacious therapies for patients. PathAI has worked closely with experts in the field of NASH/MASH for years, including leading researchers, academics, patient advocacy groups, regulatory bodies and biotechnology and pharma partners, contributing to the development of solutions for this challenging disease. Previously, this close collaboration with NASH/MASH subject matter experts led to the development and validation of AIM-NASH ™, a tool that promises to reduce the impact of pathologist scoring variability on clinical trial outcomes by assisting pathologists in grading and staging key histologic features of NASH/MASH 1,2,as well as NASH Explore ™, an AI-powered panel of more than 1000 quantitative Human Interpretable Features (HIFs) that spatially characterize NASH/MASH tissue biopsy microarchitecture at the zonal and cellular level from H&E whole slide images. Now, PathAI will build on that collaboration by bringing together a diverse group of stakeholders across academia, medicine, regulatory science, patient advocacy, and industry to inform the evolution of the company portfolio. The network’s first meeting was held in September and will be held quarterly moving forward. “Scoring liver biopsies by an expert pathologist is a crucial aspect of NASH/MASH clinical trials. However, this benchmark tool is limited both in the availability of liver pathologists and intra/inter-observer variability of their evaluation,” Pierre Bedossa, Professor of Pathology at Groupe Hospitalier Paris Nord and visiting professor at the Institute of Cellular Medicine at Newcastle University, and PathAI advisor, pointed out. “AIM-NASH developed by PathAI marks clearly a step forward. This tool alleviates some of the limitations by providing a trustworthy AI-based evaluation of liver biopsy functioning under pathologist supervision. Promising results of AIM-NASH in the context of NASH clinical trials strongly suggest that this tool may become essential to speed up drug evaluation and development for the benefit of patients.” Other members of the advisor network include: Stephen A. Harrison, medical director for Pinnacle Clinical Research and the president of Summit Clinical Research. Karoline Lackner, professor of pathology at the Medical University of Graz. Rohit Loomba, professor of medicine and director of hepatology at the University of California at San Diego. Romil Saxena, professor of pathology and laboratory medicine at Emory University School of Medicine and a diplomate of the American Board of Pathology. G. Mani Subramanian, founder, OrsoBio Chris Leptak, Senior Vice President; drugs and biologics at Greenleaf Health, Inc. “As a leader in digital pathology for liver diseases, we recognize the responsibility we have to advance the science towards effective treatments for NASH/MASH with cutting-edge technology,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “At the same time, we recognize that only by incorporating the ideas and expertise of the leading minds in MASH will we truly achieve our mutual goal of improving patient outcomes for MASH patients.” The PathAI team will be attending the American Association for the Study of Liver Diseases annual meeting November 10-14 in Boston. Schedule time to talk about how PathAI’s solutions can drive liver disease clinical development at our booth (# D3100) by emailing nash@pathai.com. Read more about PathAI’s robust AI-powered products for NASH, including AIM-NASH ™ and NASH Explore ™, on PathAI’s website. 1 Harrison et al., Retrospective AI-based Measurement of NASH Histology (AIM-NASH) Analysis of Biopsies From Phase 2 Study of Resmetirom Confirms Significant Treatment-induced Changes in Histologic Features of Nonalcoholic Steatohepatitis, EASL poster 2022. 2 Shevell et al. Comparison of manual vs machine learning approaches to liver biopsy scoring for NASH and fibrosis: a post hoc analysis of the FALCON 1 study. AASLD poster 2021 AIM-NASH & NASH Explore are authorized for research use only. Not approved for diagnostic use. About PathAI PathAI is a recognized leader in the biopharma partnering space, uniquely combining AI-powered pathology solutions with end-to-end central pathology and histology services. The company supports biopharma partners in executing clinical trials where pathology-based endpoints, biomarker classification, and/or superior histology quality are critical to successfully gauging therapeutic efficacy, accelerating drug development for complex diseases. PathAI has already supported multiple Phase 2 clinical trials in NASH, IBD, and breast cancer, as well as oncology neoadjuvant trials, and is now expanding into larger scale global Phase 3 studies, as well as additional indications. PathAI provides a fully integrated approach to clinical trials, enabling pharma partners to leverage the power of AI without the heavy lift of implementation. This helps reduce the impact of challenges associated with clinical trials, including unreliable turnaround times, variable histology, stain or scan/digitization quality, and challenging assessment of histological endpoints. The lab offers all major immunohistochemistry staining platforms, with flexible workflows across different scanners, stains, and biopsy types, which improves the quality of clinical trials. Services include access to PathAI’s extensive network of over 500 US Board Certified pathologists to perform high quality reading with rapid turnaround time in a cost-effective manner, plus seamless integration of PathAI's advanced AI-solutions to ensure high-quality, reproducible results with every scan. PathAI is headquartered in Boston, MA, and operates its CAP/CLIA-certified diagnostics clinical laboratory (formerly known as Poplar Healthcare) – one of the country’s largest anatomic pathology labs – in Memphis, TN. For more information, please visit www.pathai.com Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

November 02, 2023 10:00 AM Eastern Daylight Time

1 ... 101102103104105 ... 533